Best Practices and Research Advances in Thoracic Oncology: A Regional Series LATAM Course 2: Immunotherapy in Lung Cancer-First-Line Therapy for Advanced NSCLC without Driver Mutations

First-Line Therapy for Advanced NSCLC without Driver Mutations

Video Transcription

Video Summary

Dr. Tiziana Leal discusses first-line therapy for advanced non-small cell lung cancer (NSCLC) without driver mutations. Treatment selection involves assessing symptom burden, disease extent, histology, biomarkers, and patient preferences. For patients with high PD-L1 levels, immune checkpoint inhibitor monotherapy is typically used. Those with low or negative PD-L1 often receive a combination of chemotherapy and immunotherapy, or dual checkpoint inhibitors with or without chemotherapy. Key clinical trials (e.g., Keynote 024, Empower 110) show improved survival with these approaches. CTLA-4 inhibitors play a role in certain patient subsets, including those with specific molecular alterations.

Asset Subtitle

Ticiana Leal, MD

Keywords

NSCLC

immune checkpoint inhibitors

PD-L1

chemotherapy

CTLA-4 inhibitors